NDAORALTABLETPriority Review
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIKAFTA is a copackaged oral triple combination of elexacaftor, tezacaftor, and ivacaftor that treats cystic fibrosis by correcting defective CFTR protein trafficking and function. Elexacaftor and tezacaftor work together to increase CFTR protein delivery to the cell surface, while ivacaftor enhances the gating function of CFTR at the surface, resulting in increased chloride transport and clinical benefit across multiple CFTR variants.
Peak11.8 years to LOE
TRIKAFTA is at peak commercial performance as the standard-of-care CFTR modulator, driving significant sales and requiring sizable field, medical affairs, and commercial operations teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations
Started Nov 2016
2 enrolled
Cystic Fibrosis
Career Relevance
Working on TRIKAFTA offers exposure to a peak-stage, precision medicine blockbuster with 231 linked job opportunities across commercial, clinical, and operational functions. The breadth of career paths reflects TRIKAFTA's market dominance and the complexity of managing a multi-component therapy across diverse patient genotypes.
Director
Worked on TRIKAFTA (COPACKAGED) at Vertex Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.